Monofree (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This inhibition relaxes the sphincter muscle and reduces ciliary muscle tone, leading to pupil dilation (mydriasis) and loss of accommodation (cycloplegia), which facilitates ocular assessment and treatment.

The prescribed dose of Monofree is determined by the treating eye‑care professional. Typically, a few drops are instilled in the affected eye(s) shortly before the examination or procedure, but the exact regimen, frequency, and number of applications are set by the prescriber.

Safety data for tropicamide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under medical supervision.

To order Monofree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Monofree (tropicamide) provides rapid onset of dilation with a relatively short duration of action, making it suitable for routine examinations. Phenylephrine, an adrenergic mydriatic, often produces a longer‑lasting effect but may cause more systemic cardiovascular stimulation. Tropicamide’s antimuscarinic profile generally results in fewer systemic side effects, though it can precipitate angle‑closure glaucoma in susceptible eyes.

Monofree should be stored at room temperature, below 25 °C, in its original container. Protect the product from direct light, moisture and extreme temperature fluctuations. Keep the vial tightly sealed when not in use and discard any solution that appears discolored or contaminated.

Monofree is applied topically as an ophthalmic solution. The usual method is to instill one to two drops into the conjunctival sac of the target eye(s) using a sterile dropper. Administration is performed by a qualified eye‑care professional or under their instruction, ensuring the dropper does not touch the ocular surface.

The most serious adverse events include acute angle‑closure glaucoma, which can cause sudden vision loss, and severe allergic reactions such as anaphylaxis. Systemic anticholinergic effects—though rare—may manifest as tachycardia, dry mouth, or urinary retention, especially in patients taking other anticholinergic medications.

Monofree should be avoided in individuals with known narrow‑angle or acute angle‑closure glaucoma, hypersensitivity to tropicamide or any excipients, and in children unless specifically prescribed by an ophthalmologist. Caution is also advised for patients on multiple anticholinergic drugs or those with significant systemic diseases that could be aggravated by anticholinergic activity.